Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Narcolepsy

"Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Narcolepsy is a sleep disorder characterized by excessive sleepiness, sleep paralysis, hallucinations, and in some cases episodes of cataplexy (partial or total loss of muscle control, often triggered by a strong emotion such as laughter). Narcolepsy type 1 occurs when nearly all of the neurons that contain orexin (also called hypocretin) are lost.  The reason for this is not fully understood, but it is thought to be an autoimmune process possibly triggered by an infection. HLA haplotype DQB1*0602 is present in 95% of narcolepsy type 1 patients, but this is also present in about 20% of the general population without narcolepsy. The cause of narcolepsy type 2 is not entirely clear. Current hypotheses include less destruction of orexin cells, impaired orexin receptor signaling, or an unknown mechanism.

Narcolepsy classified into two types;

Narcolepsy Type 1 – This type of narcolepsy involves a combination of excessive daytime sleepiness and one or both of the following:

Cataplexy is when you have attacks that cause a sudden loss of muscle tone while you are awake. It may lead to slurred speech and buckling knees, or in more severe cases complete paralysis. These events are usually triggered by strong emotions such as joy, surprise, laughter or anger.

Low or absent CSF hypocretin-1 levels. Narcolepsy type 1 is caused by a deficiency of hypocretin (orexin). A patient with low hypocretin has narcolepsy type 1, even if they don’t exhibit cataplexy.

Narcolepsy Type 2 – This type of narcolepsy occurs when you have continuous excessive sleepiness but no cataplexy. You may take a nap for a couple of hours and wake up feeling refreshed. But after a short time, you feel tired again.

Epidemiology- according to Thelansis Narcolepsy prevalence is 14 per 100,000 people for narcolepsy type 1 and 65.4 per 100,000 people for narcolepsy type 2. Incidence is highest in the late teens to early twenties with a 50% greater female predominance in the U.S

Competitive landscape of Narcolepsy includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Narcolepsy across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Narcolepsy Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No     Asset     Company              Partner            Phase

1            Dexedrine          Amneal Pharmaceuticals, Inc.     GlaxoSmithKline              Approved (Generic Competition)

2            Nuvigil  Teva Pharmaceutical Industries Ltd.        N/A       Approved (Generic Competition)

3            Provigil (Sparlon)            Teva Pharmaceutical Industries Ltd.              Takeda Pharmaceutical Approved (Generic Competition)

4            Sunosi  Jazz Pharmaceuticals plc              SK Biopharmaceuticals; Shionogi; Aerial BioPharma         Approved

5            Wakix   Harmony Biosciences Holdings, Inc.         Bioprojet; Ferrer; Endo International         Approved

6            Xyrem   Jazz Pharmaceuticals plc              UCB; Bausch Health              Approved

7            Xywav   Jazz Pharmaceuticals plc              N/A       Approved

8            FT218    Avadel Pharmaceuticals plc         N/A       III

9            Quilience            NLS Pharmaceutics AG   Adare   III

10          AXS-12  Axsome Therapeutics, Inc.          Pfizer    II

11          BTD-001             Balance Therapeutics, Inc.           N/A       II

12          SUVN-G3031      Suven Life Sciences Ltd. N/A       II

13          THN102              TheraNexus       N/A       II

14          TAK-925              Takeda Pharmaceutical Co. Ltd. N/A       I

15          TAK-994              Takeda Pharmaceutical Co. Ltd. N/A       I

16          XWL-008             XWPharma        N/A       I

17          XW10172            XWPharma        N/A       Status to confirm

18          EVT 501              Evotec SE            N/A       Preclinical

19          SLS-010 Seelos Therapeutics, Inc.             Ligand   Preclinical